Abstract:Purpose: Modulation of the BMP pathway remains an attractive target for development of novel anabolic treatments for osteoarthritis. We are aiming to identify chondro-specific small molecule enhancers of the BMP pathway. The ideal compound promotes the anabolic potential of the chondrocytes without pushing the cells into hypertrophy and does not induce/enhance TGFb-driven tumor formation/metastasis. We used a “chemical biology approach” whereby 25K compounds were screened in a BMP reporter cell-line for their enhancing activity. Next, we applied “phenotypic filter assays” to identify compounds with the desired profile. Like this, we take full advantage of the diversity available in the chemical library and maximize our chances to come up with innovative modulators of BMP pathway possessing tissue selective capacities and no/minor side effects. Methods: 25K compounds were screened in a BMP reporter cell line for their BMP enhancing potential at 10μM (%PAC > 68%). Cytotoxic and general enhancers have been removed (NFkB counterscreen). Commercially available hit-analogues were ordered, evaluated in the BMP reporter (hit explosion) and in primary human adult articular chondrocytes in alginate bead culture system at 10μM to select promising series. The effect on aggrecan production was evaluated in the interterritorial matrix of the beads using a commercially available ELISA and gene expression profile was studied on the cell pellet using qRT-PCR (COL2, ACAN, SOX9, MIA, COL1, BGLAP). Medicinal chemistry efforts produced > 300 derivatives of promising series. Potency was evaluated as previously described and used to identify SAR of the series. In addition, tissue selectivity (osteogenic differentiation assay, TGFb-driven tumor formation in lung fibroblasts and breast cancer cell invasion model) and pathway specificity (TGFb reporter/NFkB (TNF) reporter) were performed to eliminate series/compounds showing unselective/aspecific side effects. Results: From the 25K compounds, hits belonging to 12 chemical series were identified showing > 68% enhancement in the BMP reporter, showing no toxicity in hepG2 cells nor general transcriptional activation. Hit explosion confirmed the initial results and provided basic SAR. Using primary human chondrocytes the most promising series showed a concentration-dependent increase of aggrecan production; COL2, ACAN and MIA upregulation; no effect on hypertrophy-associated genes. The selected series are pathway specific (no TGFb enhancement - no TNF enhancement), tissue selective (no enhancement of osteogenic differentiation) and enhance/induce no TGFb-driven tumor formation/metastasis. Following hit to lead optimization, SAR has been refined and potency (EC50) already improved to sub-micromolar range. Conclusions: Using this chemical biological approach we identified novel series showing pro-anabolic properties in the articular cartilage, tissue selectivity and pathway specificity, with no to minimal side effects (toxicity, TGFb-driven tumor formation/metastasis) and a clear structure activity relationship. Further in vitro and in vivo activity testing is ongoing and results are expected soon.

Disease Modifying Osteoarthritis Drug Discovery Using A Temporal Phenotypic Reporter In 3D Aggregates of Primary Human Chondrocytes

Phage Display Identified Peptide with Selectivity for Human Osteoarthritic Chondrocytes

P93 Angiogenesis in Human and Guinea Pig Osteoarthritis

Dehydroepiandrosterone and Experimental Osteoarthritis.

A single-cell mass cytometry platform to map the effects of preclinical drugs on cartilage homeostasis

Exploring Osteoarthritis Dynamics: Patient-Specific Cartilage Samples in an Organ-on-a-Chip Model

A Three-Dimensionally Engineered Biomimetic Cartilaginous Tissue Model for Osteoarthritic Drug Evaluation

Angiopoietin-like 3-Derivative LNA043 for Cartilage Regeneration in Osteoarthritis: a Randomized Phase 1 Trial

In silico, in vitro, and in vivo models reveal EPHA2 as a target for decreasing inflammation and pathological endochondral ossification in osteoarthritis

A programmable arthritis-specific receptor for guided articular cartilage regenerative medicine

Integrative epigenomics, transcriptomics and proteomics of patient chondrocytes reveal genes and pathways involved in osteoarthritis

Saxagliptin suppresses degradation of type II collagen and aggrecan in primary human chondrocytes: a therapeutic implication in osteoarthritis.

Novel Ex Vivo Human Osteochondral Explant Model of Knee and Spine Osteoarthritis Enables Assessment of Inflammatory and Drug Treatment Responses

Investigating mechanical and inflammatory pathological mechanisms in osteoarthritis using MSC-derived osteocyte-like cells in 3D

Identification of Enhancers of BMP Signaling Pathway with Cartilage Anabolic Properties

Development of a Microfluidic Vascularized Osteochondral Model as a Drug Testing Platform for Osteoarthritis

Use of Cartilage Derived From Murine Induced Pluripotent Stem Cells for Osteoarthritis Drug Screening

Identification of biomarkers and potential drug targets in osteoarthritis based on bioinformatics analysis and mendelian randomization

Promoting chondrogenesis by targeted delivery to the degenerating cartilage in early treatment of osteoarthritis

Three-dimensional osteochondral microtissue to model pathogenesis of osteoarthritis

A human organoid drug screen identifies α2-adrenergic receptor signaling as a therapeutic target for cartilage regeneration